



Technology Advisory Committee A Interests Register Talazoparib for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2 mutations [ID1342]

Publication Date: 21 February 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Professor Andrew Tutt	Clinical expert	Direct – financial	Professor Andrew Tutt receives from the ICR a share of royalties/payments made to ICR by AZ from sales of olaparib and other PARP inhibitors. Pfizer -Personal fees /Advisory Board related to targeted therapies in DNA repair deficient. Vertex - Personal fees from /Advisory Board related to targeted therapies in DNA repair deficient.	29/12/2022	N/A	It was agreed that Andrew's declaration would not prevent him from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Artios			
			- Personal fees / Advisory			
			Board related to targeted			
			therapies in DNA repair			
			deficient.			
			Prime Oncology			
			- Personal fees / Advisory			
			Board related to targeted			
			therapies in DNA repair			
			deficient.			
			<u>Inbiomotion</u>			
			- Personal fees / Scientific Ad			
			Board function and stock			
			options			
			MD Anderson			
			- personal fees / Moon shot			
			Breast Cancer scientific			
			advisory board honoraria.			
			Medscape Education			
			honorarium from Merck			
			educational grant			
			- personal fees / speaker for			
			a video series tentatively			
			titled "Understanding the			



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Rationale for PARP Inhibitors and their Combination with Immunotherapy in the Treatment of Various Solid Tumours			
			SABCS Mini Symposium- speaker honorarium			
			EMPartners-			
			Personal fees / Advisory Board			
			Gilead:			
			-Personal fees for Ad Board & payments to my institution			
			GBCC 2022			
			-Speaking role personal honorarium			
			Cancer Panel			
			-Speaker personal honorarium			



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Research to Practice			
			-Personal honorarium for research survey			
			AACR Team prize			
			-Personal honorarium for Team prize			
			Private practise @ HCA – LOC-			
			-Private oncology hospital clinics in London treating			
			patients with germline BRCA1/2 mutations in breast			
			cancer involving all forms of systemic therapy, including			
			PARP inhibitors licensed in breast cancer indications.			
			Director, Breast Cancer Now			
			Research Unit, King's			
			College London &			
			<u>Director, Breast Cancer Now</u> <u>Research Centre, The</u>			



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Institute of Cancer Research, London -Full time dual role as Director across two Institutes. Salary paid. Honorary Consultant Clinical Oncologist @ Guys' & St Thomas Hospital NHS Foundation Trust- -Treating patients in NHS capacity.			
Professor Andrew Tutt	Clinical expert	Direct – Nonfinancial	ESMO Guidelines - Committee Member ESMO Breast 2022 - Scientific Committee ESMO 2023 Planning – Scientific Committee Member NCRI Strategy Committee – Member	29/12/2022	N/A	It was agreed that Andrew's declaration would not prevent him from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Early Breast Cancer Trialists'			
			Collaborative Group- Member			
			Global Study Chair OlympiA			
			Trial Steering Committee			
			CRUK- Expert panel member			
			/ chair for Clinical Research			
			Expert Review Panel			
			Director, Breast Cancer Now			
			Research Unit, King's			
			College London			
			Director, Breast Cancer Now			
			Research Centre, The			
			Institute of Cancer Research,			
			London			
			Honorary Consultant Clinical			
			Oncologist @ Guys' & St			
			Thomas Hospital NHS			
			Foundation Trust,			
			Honorary Consultant Clinical			
			Oncologist @ The Royal			
			Marsden Hospital NHS			
			Foundation Trust			



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Professor Andrew Tutt	Clinical expert	Indirect	AstraZeneca -Financial support to my academic & hospital institutions for costs associated with global academic study chair and local site costs for OlympiA trial / Travel expenses related to any trial related travel / Payments to Institution through Breast International Group for trial conduct in OlympiA trial and through CRO's for commercial parp inhibitor trials / AstraZenecaroyalties paid to Institute of Cancer Research for the use of parp inhibitors in DNA deficient cancers, and personally to me through ICR rewards to Inventor's scheme. Merck KGAA -Local site trial support costs associated with clinical trial DNA	29/12/2022	N/A	It was agreed that Andrew's declaration would not prevent him from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Medivation - Financial support for research at ICR			
			Myriad Genetics - Financial support for research at ICR			
			AZ ESMO Symposium			
			Paid to ICR for speaker role VJ oncology			
			Roundtable- payment to institution			
			GE Healthcare			
			Meeting – payment to institution			
			Gilead:			
			-Personal fees for Ad Board & payments to my institution			



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Innovation in Breast Cancer			
			Symposium:			
			-Fees to my King's Institution			
			for speaking role at			
			conference			
			SABCS 2021 conference:			
			-Fees to Institute of Cancer			
			Research for speaking role at			
			conference.			
			Breast Cancer Now Charity			
			- Grant funded to study			
			homologous recombination			
			deficient breast and other			
			cancers, BCN receive			
			payments through			
			AstraZeneca related to PARP			
			inhibitor patents.			
			CRUK			
			- Grant funded to study			
			homologous recombination			
			deficient breast and other			
			cancers, CRUK receive			
I			payments through			



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			AstraZeneca related to PARP inhibitor patents / personal fees / Honoraria associated with function as Deputy Chair and reviewer for CRUK clinical research.			
Dr Jennifer Glendenning	Clinical Expert	Indirect	Advisory board payments Exact Sciences and Roche.	22/11/2022	N/A	It was agreed that Jennifer's declaration would not prevent her from providing expert advice to the committee.